A novel [1,2,4]triazolo[1,5-a]pyridine compound is disclosed that has a formula represented by the following:This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis； and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.本發明揭示一種新穎[1,2,4]三唑并[1,5-a]吡啶化合物，其具有由下式代表之式：該化合物可製備為醫藥組合物，且可用於防止及治療包括人類之哺乳動物的各種病況，該等病況之非限制性實例包括涉及軟骨降解、骨及/或關節降解之疾病，例如骨關節炎；及/或涉及炎症或免疫應答之病況，例如克羅恩氏病(Crohn's disease)、類風濕性關節炎、銀屑病、過敏性呼吸道疾病(例如哮喘、鼻炎)、幼年型特發性關節炎、結腸炎、炎性腸疾病、內毒素引發的疾病狀態(例如，搭橋手術後併發症或促成(例如)慢性心力衰竭之慢性內毒素狀態)、涉及軟骨轉換損傷之疾病(例如，涉及軟骨細胞之合成代謝刺激的疾病)、先天軟骨畸形、與IL6分泌過多相關之疾病及移植排斥(例如器官移植排斥)及增生性疾病。
